Promising results for cancer-immunotherapies revealed!
Data from phase 3 trials for the breakthrough immunotherapies pembrolizumab and nivolumab have shown exiting results for the treatment of melanoma, non-small cell lung cancer and renal cancer. The data was presented last week at the convention of the American Society of Clinical Oncology (ASCO) 2015.
Many media have reported about these results, a short overview can be found below:
Bristol-Myers Squibb Has A Cancer Breakthrough. Here's Why It Should Cut The Price Forbes By Matthey Herper, June 1, 2015